西山 博之(ニシヤマ ヒロユキ)

研究者情報全体を表示

論文

• Patient characteristics correlate with diagnostic performance of photodynamic diagnostic assisted transurethral resection of bladder tumors: A retrospective, single-center study
  Suzuki Shuhei; Nagumo Yoshiyuki; Ikeda Atsushi; Kojo ...
  PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY/46, 2024-03-18
  
  PubMed
• Objective evaluation of gaze location patterns using eye tracking during cystoscopy and artificial intelligence-assisted lesion detection
  Ikeda Atsushi; Izumi Kazuya; Katori Kensuke; Nosato H...
  Journal of endourology/Epub, 2024-03-25
  
  PubMed
• 限局性前立腺癌に対する中等度寡分割陽子線治療：第2相試験の報告
  村上 基弘; 石川 仁; 飯泉 天志; 水本 斉志; 奥村 敏之; 西山 博之; 五所 正彦; 櫻井 英幸
  第37回高精度放射線外部照射部会学術大会　プログラム・抄録集/pp.66-66, 2024-03-02
• The prognostic impact of treatment centralization in patients with testicular germ cell tumors: analysis of hospital-based cancer registry data in Japan
  Suzuki Shuhei; Nagumo Yoshiyuki; Kandori Shuya; Kojo Kou...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/29(3)/pp.318-324, 2024-01-24
  
  PubMed
• Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022
  Yanagita Motoko; Muto Satoru; Nishiyama Hiroyuki; Ando...
  CLINICAL AND EXPERIMENTAL NEPHROLOGY/Epub, 2023-10-25
• The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapy
  Kikuchi Hiroshi; Abe Takashige; Miyake Makito; Miyata ...
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY/Epub, 2023-11-16
• Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non-muscleinvasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu ′erin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.
  Necchi Andrea; Roumiguie Mathieu; Esen Ahmet Adil; Leb...
  JOURNAL OF CLINICAL ONCOLOGY/41(6), 2023-02-20
• Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HRNMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.
  Catto James W. F.; Ben Tran; Master Viraj A.; Roupret ...
  JOURNAL OF CLINICAL ONCOLOGY/41(6), 2023-02-20
• Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association
  Mori Kazuyuki; Hatakeyama Shingo; Enokida Hideki; Miya...
  INTERNATIONAL JOURNAL OF UROLOGY/Epub, 2023-12-19
• THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non emuscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guerin (BCG) treatment
  Catto J. W. F.; Tran B.; Roupret M.; Gschwend J. E.; ...
  ANNALS OF ONCOLOGY/34(2)/pp.S1341-S1342, 2023-10
• Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories
  Ku Ja Hyeon; Lee Lui Shiong; Lin Tzu-Ping; Kikuchi Ei...
  INTERNATIONAL JOURNAL OF UROLOGY/Epub, 2023-10-06
• Comparison of perioperative outcomes and complications between intracorporeal, extracorporeal, and hybrid ileal conduit urinary diversion during robot-assisted radical cystectomy: a comparative propensity score-matched analysis from nationwide multi-institutional study in Japan
  Morizane Shuichi; Nakane Keita; Tanaka Toshiaki; Zenna...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/Epub, 2023-10-21
• The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database
  Koguchi Tomoyuki; Naito Sei; Hatakeyama Shingo; Numaku...
  CANCER MEDICINE/Epub, 2023-10-31
• Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group
  Horie Shigemitsu; Naito Sei; Hatakeyama Shingo; Kandor...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/28(11:SI)/pp.1538-1544, 2023-11
• Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.
  Hoimes Christopher J.; Loriot Yohann; Bedke Jens; Nish...
  JOURNAL OF CLINICAL ONCOLOGY/41(6), 2023-02-20
• Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial
  Kimura Tomokazu; Ishikawa Hitoshi; Nagumo Yoshiyuki; S...
  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS/117(3)/pp.644-651, 2023-11-01
• Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition
  Mishima Saori; Naito Yoichi; Akagi Kiwamu; Hayashi Na...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/28(10)/pp.1237-1258, 2023-10
• Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
  Ando Yuichi; Nishiyama Hiroyuki; Shimodaira Hideki; Ta...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/28(10)/pp.1315-1332, 2023-10
• Sexual function using the EORTC QLQ-TC26 in testicular cancer survivors: A multi-institutional, cross-sectional study
  Koyama Juntaro; Yamashita Shinichi; Kakimoto Kenichi; ...
  INTERNATIONAL JOURNAL OF UROLOGY/Epub, 2023-07-31
• Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
  Nishiyama Hiroyuki; Inoue Takamitsu; Koizumi Yuichi; K...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/28(10)/pp.1298-1314, 2023-10
• Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study
  Nishiyama Hiroyuki; Tsuzuki Toyonori; Ohyama Chikara; ...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/28(10)/pp.1398-1410, 2023-10
• Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
  Nishiyama Hiroyuki; Tanaka Yu; Hamada Masahiro; Ozaki ...
  BMC CANCER/23(1), 2023-06-20
• Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma
  Hamada Kazuki; Nagumo Yoshiyuki; Kandori Shuya; Tanuma...
  ONCOLOGY LETTERS/26(3), 2023-09
• Re: Predictive Biomarkers for Survival Benefit With Ramucirumab in Urothelial Cancer in the RANGE Trial Editorial Comment
  van der Heijden M. S.; Powles T.; Petrylak D.; de Wit ...
  JOURNAL OF UROLOGY/209(1)/pp.291-291, 2023-01
• Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors
  Naito Yoichi; Mishima Saori; Akagi Kiwamu; Hayashi Na...
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY/28(7:SI)/pp.827-840, 2023-07
• さらに表示...